<DOC>
	<DOCNO>NCT02646566</DOCNO>
	<brief_summary>Double-blind , randomise , parallel-group , placebo-controlled , adaptive , seamless , dose-selecting study compare efficacy APD421 placebo treatment establish PONV , patient prior PONV prophylaxis .</brief_summary>
	<brief_title>Study APD421 PONV Treatment ( Prior Prophylaxis )</brief_title>
	<detailed_description />
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Postoperative Nausea Vomiting</mesh_term>
	<criteria>Inclusion criterion : Male female patient â‰¥ 18 year age Provision write informed consent Patients schedule undergo elective surgery ( open laparoscopic technique ) general anaesthesia ( total intravenous anaesthesia propofol ) expect last least one hour induction anaesthesia extubation Patients judge investigator moderate high risk experience PONV . In form judgment , investigator pay particular attention risk factor past history PONV and/or motion sickness ; habitual nonsmoking status ; female sex ; likely use opioid analgesia postoperatively . For female childbearing potential : ability willingness use highly effective form contraception ( define ICH M3 guidance , e.g. , abstinence sexual intercourse , surgical sterilisation ( subject partner ) , combine oral contraceptive pill , doublebarrier method contraception either intrauterine device ( IUD ) occlusive cap spermicide , conjunction partner 's use condom , method combination method failure rate generally consider &lt; 1 % per year ) date screen least 48 hour administration study drug In order eligible randomisation , subject must also : ( ) experience first episode PONV 24 hour end operation ( wound closure ) prior discharge hospital ( `` qualify PONV episode '' ) , already receive antiemetic treatment ; ( ii ) receive dopamineantagonist agent likely prevent treat nausea vomiting ( give prophylaxis otherwise ) period 24 hour prior start operation time qualify PONV episode . Patients schedule undergo transplant surgery surgery postoperative emesis may pose significant danger patient Patients plan receive local anaesthetic and/or regional neuraxial ( intrathecal epidural ) block Patients receive APD421 active ingredient indication within last 2 week Patients allergic APD421 active ingredient excipients APD421 Patients significant , ongoing history vestibular disease dizziness Patients know prolactindependent tumour ( e.g . pituitary gland prolactinoma breast cancer ) phaeochromocytoma . Patients document suspected alcohol substance abuse within past 6 month . Patients direct indirect evidence clinically significant hypokalaemia , serum potassium level &lt; 3.0 mmol/L . Patients receive postoperative period , prior receive study drug , medication substantial risk induce torsades de pointes , include Class Ia antiarrhythmic agent quinidine , disopyramide , procainamide ; Class III antiarrhythmic agent amiodarone sotalol ; medication bepridil , cisapride , thioridazine , methadone , IV erythromycin , IV vincamine , halofantrine , pentamidine , sparfloxacin , etc . Patients document , clinically significant cardiac arrhythmia congenital long QT syndrome . Patients pregnant breast feed . Patients treat levodopa . Patients diagnose Parkinson 's disease . Patients receive emetogenic anticancer chemotherapy previous 4 week . Patients history epilepsy . Any concurrent disease illness , opinion investigator make patient unsuitable study . Patients previously participate study participate another interventional clinical study involve pharmacological therapy within previous 28 day ( long exclusion period , require national local regulation ) . Where local laws/regulations require : patient legal protection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>